Follow-The-Filings

Security · featured owners

SGMT Sagimet Biosciences Inc-A

COM SER A Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 0.3%
  • $5M
  • 2 new

Who owns this now

Largest portfolio weights among featured holders · max 0.3% (Palo Alto Investors) · not free-float ownership

  1. Palo Alto Investors new 0.27%
  2. Farallon Capital Management new 0.01%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Farallon Capital Management 2026 Q2 0.01% New 0.01% 415,000 $3M history
Palo Alto Investors 2026 Q2 0.27% New 0.27% 250,000 $2M history

2 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2M — —
Net income -$27.88M -$45.57M -$51.04M
Net margin * -1393.8% — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $96.65M $152.77M $116.4M
Total non-current assets * $0.073M $7.48M $0.078M
Total assets $96.72M $160.26M $116.48M
Total current liabilities $5.65M $4.45M $5.1M
Total non-current liabilities * $0.00 — —
Total equity $91.06M $155.8M $111.38M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$23.77M -$42.44M -$45.65M
Cash from investing $12.58M -$61.68M $4.56M
Cash from financing $86.17M $104.82M $0.275M
Net change in cash * $74.98M $0.701M -$40.82M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders

Q2 2026

period archive